Myosin-neonatal inhibitors are a class of chemical compounds specifically designed to target and inhibit the function of the neonatal isoform of myosin, a motor protein that plays a crucial role in muscle contraction and various cellular movements. Myosin is a superfamily of motor proteins that interact with actin filaments to generate force and movement within cells. The neonatal isoform of myosin, often expressed during early developmental stages, is particularly important in the formation and function of muscle tissue in neonates. This isoform is structurally distinct from the adult forms of myosin, which allows it to fulfill specialized roles during the early stages of muscle development. By inhibiting the neonatal isoform of myosin, researchers can study its specific contributions to muscle formation, differentiation, and function during development.
In research settings, myosin-neonatal inhibitors are valuable tools for exploring the role of this specific myosin isoform in the development and function of neonatal muscle tissue. By blocking the activity of neonatal myosin, scientists can investigate how the inhibition affects muscle fiber formation, contractile properties, and the overall development of muscle tissue during the neonatal period. These inhibitors allow researchers to dissect the differences between neonatal and adult myosin isoforms in terms of their structural and functional properties, providing insights into the specialized roles that neonatal myosin plays in muscle physiology. Additionally, myosin-neonatal inhibitors help in understanding the regulatory mechanisms that control the expression and activity of different myosin isoforms during development, contributing to a broader understanding of muscle biology and the molecular processes that drive muscle differentiation and maturation. Through these studies, the use of myosin-neonatal inhibitors enhances our knowledge of the critical role that myosin isoforms play in muscle development and the specific functions of neonatal myosin in early life stages.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(±)-Blebbistatin | 674289-55-5 | sc-203532B sc-203532 sc-203532A sc-203532C sc-203532D | 5 mg 10 mg 25 mg 50 mg 100 mg | $183.00 $313.00 $464.00 $942.00 $1723.00 | 7 | |
Selective inhibitor of myosin II, can inhibit MYH8 through its effects on myosin. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Inhibits Rho-associated kinase, thus reducing muscle contractility and potentially inhibiting MYH8. | ||||||
ML-9 | 105637-50-1 | sc-200519 sc-200519A sc-200519B sc-200519C | 10 mg 50 mg 100 mg 250 mg | $112.00 $449.00 $673.00 $1224.00 | 2 | |
Inhibits myosin light chain kinase, which can in turn reduce the activity of MYH8. | ||||||
Wiskostatin | 253449-04-6 | sc-204399 sc-204399A sc-204399B sc-204399C | 1 mg 5 mg 25 mg 50 mg | $49.00 $124.00 $441.00 $828.00 | 4 | |
Inhibits the N-WASP-Arp2/3 pathway, potentially reducing the activity of MYH8 in cellular processes. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $31.00 $128.00 $454.00 | 45 | |
p38 MAPK inhibitor, can influence MYH8 by inhibiting muscle differentiation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor, can indirectly inhibit the activity of MYH8 in stress response. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
Inhibits MEK, which can affect pathways in which MYH8 is involved. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
PKC inhibitor, can affect MYH8 function via PKC-related pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor that can indirectly affect MYH8 functionality. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Another PI3K inhibitor, can affect MYH8 activity by inhibiting signaling pathways. | ||||||